TRADING UPDATES: East Star Verkhuba update; BSF distribution deal
11th Aug 2026 18:23
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
| Price | 1.25p on 21-08-2026 at 18:35:08 |
|---|---|
| Change | -0.075p -5.66% |
| Buy | 1.30p |
| Sell | 1.20p |
| Last Trade: | Buy 7,500.00 at 1.278p |
| Day's Volume: | 2,521,803 |
| Last Close: | 1.25p |
| Open: | 1.325p |
| ISIN: | GB0034330679 |
| Day's Range | 1.25p - 1.36p |
| 52wk Range: | 0.85p - 7.50p |
| Market Capitalisation: | £14.21m |
| VWAP: | 1.277406p |
| Shares in Issue: | 1.14b |
Cellbxhealth (CLBX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 7,500 | 1.278p | Ordinary |
16:28:56 - 21-Aug-26 |
| Buy* | 419,405 | 1.278p | Ordinary |
16:20:24 - 21-Aug-26 |
| Buy* | 15,254 | 1.285p | Ordinary |
16:17:45 - 21-Aug-26 |
| Sell* | 156,734 | 1.21p | Ordinary |
16:14:09 - 21-Aug-26 |
| Sell* | 297,942 | 1.23p | Ordinary |
16:06:53 - 21-Aug-26 |
| Buy* | 76,737 | 1.298p | Ordinary |
16:03:55 - 21-Aug-26 |
| Buy* | 1,538 | 1.30p | Ordinary |
15:23:44 - 21-Aug-26 |
| Buy* | 30,256 | 1.289p | Ordinary |
15:17:24 - 21-Aug-26 |
| Sell* | 257,432 | 1.26p | Ordinary |
15:13:39 - 21-Aug-26 |
| Sell* | 3,063 | 1.26p | Ordinary |
15:13:28 - 21-Aug-26 |
Cellbxhealth (CLBX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 11th Aug 2026 7:00 am | RNS | Parsortix CTCs used for Brain Cancer detection |
| 3rd Aug 2026 7:00 am | RNS | Parsortix CTCs used for ADC target assessment |
| 16th Jul 2026 7:00 am | RNS | Issue of Share Options |
| 15th Jul 2026 7:00 am | RNS | Q2 and First Half Year Results ended 30 June 2026 |
| 14th Jul 2026 9:46 am | RNS | Result of AGM |
| 14th Jul 2026 7:00 am | RNS | AGM Statement |
| 6th Jul 2026 4:45 pm | RNS | Directorate change |
| 22nd Jun 2026 7:00 am | RNS | Preliminary Results |
| 16th Jun 2026 7:00 am | RNS | Notice of Results |
| 29th May 2026 7:00 am | RNS | MSA with Global Pharmaceutical Company |